Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC25A52 is a mitochondrial membrane carrier protein that mediates the import of NAD(+) into mitochondria, participating in the regulation of mitochondrial metabolism and NAD(+) homeostasis[2][3]. SLC25A52 is a member of the solute carrier family 25 (SLC25), sharing high sequence similarity with SLC25A51, but is expressed most abundantly in the testis with low or undetectable levels in other tissues[1][2]. Its physiological function overlaps with SLC25A51, but SLC25A52-mediated transport is not essential for mitochondrial NAD(+) import under most conditions. The precise transport mechanism (uniport vs. antiport, electrogenicity, substrate specificity) remains to be elucidated[2][3]. There are emerging genetic associations with rare mitochondrial disorders, but no current approved drugs are known to target this transporter directly, and its value as a drug target or biomarker remains unclear.
NAD(+) transport into mitochondria (mechanism not yet fully elucidated; possibly uniport or antiport)[2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial nicotinamide adenine dinucleotide transporter SLC25A52 (SLC25A52).